Effects of KPC Variant and Porin Genotype on the <i>In Vitro</i> Activity of Meropenem-Vaborbactam against Carbapenem-Resistant <i>Enterobacteriaceae</i>

William R. Wilson, Ellen G Kline, Chelsea E Jones, Kristin M. Morder, Roberta T. Mettus, Yohei Doi, M. Hong Nguyen, Cornelius J. Clancy, Ryan K. Shields

Antimicrobial Agents and Chemotherapy · 2019 · 86 citations · 28 references

DOIFull text

Open access

Concepts

Abstract

Meropenem-vaborbactam is a new agent with the potential to treat carbapenem-resistant Enterobacteriaceae (CRE) infections. We describe the in vitro activity of meropenem-vaborbactam against representative CRE genotypes and laboratory-engineered Escherichia coli isolates harboring mutant bla KPC genes associated with ceftazidime-avibactam resistance.

References

28